Frontotemporal Dementia: A Clinical Review

Harri Sivasathiaseelan; Charles R. Marshall; Jennifer L. Agustus; Elia Benhamou; Rebecca L. Bond; Janneke E. P. van Leeuwen; Chris J. D. Hardy; Jonathan D. Rohrer; Jason D. Warren

doi:10.1055/s-0039-1683379

Seminars in Neurology, Table of Contents

Semin Neurol 2019; 39(02): 251-263
DOI: 10.1055/s-0039-1683379

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Frontotemporal Dementia: A Clinical Review

Harri Sivasathiaseelan

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Charles R. Marshall

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

²Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

,

Jennifer L. Agustus

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Elia Benhamou

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Rebecca L. Bond

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Janneke E. P. van Leeuwen

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Chris J. D. Hardy

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Jonathan D. Rohrer

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

,

Jason D. Warren

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

› Author Affiliations

Abstract

Frontotemporal dementias are a clinically, neuroanatomically, and pathologically diverse group of diseases that collectively constitute an important cause of young-onset dementia. Clinically, frontotemporal dementias characteristically strike capacities that define us as individuals, presenting broadly as disorders of social behavior or language. Neurobiologically, these diseases can be regarded as “molecular nexopathies,” a paradigm for selective targeting and destruction of brain networks by pathogenic proteins. Mutations in three major genes collectively account for a substantial proportion of behavioral presentations, with far-reaching implications for the lives of families but also potential opportunities for presymptomatic diagnosis and intervention. Predicting molecular pathology from clinical and radiological phenotypes remains challenging; however, certain patterns have been identified, and genetically mediated forms of frontotemporal dementia have spearheaded this enterprise. Here we present a clinical roadmap for diagnosis and assessment of the frontotemporal dementias, motivated by our emerging understanding of the mechanisms by which pathogenic protein effects at the cellular level translate to abnormal neural network physiology and ultimately, complex clinical symptoms. We conclude by outlining principles of management and prospects for disease modification.

Keywords

frontotemporal dementia - primary progressive aphasia - behavioral variant FTD - semantic dementia

Full Text

References

References
1 Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ 2013; 347: f4827
2 Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem 2016; 138 (Suppl. 01) 6-31
3 Marshall CR, Hardy CJD, Volkmer A. , et al. Primary progressive aphasia: a clinical approach. J Neurol 2018; 265 (06) 1474-1490
4 Pick A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prag Med Wochenschr 1892; 17: 165-167
5 Pick A. Über primare progressive Demenz bei Erwachsenen. Prag Med Wochenschr 1904; 29: 417-420
6 Warrington EK. The selective impairment of semantic memory. Q J Exp Psychol 1975; 27 (04) 635-657
7 Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol 1982; 11 (06) 592-598
8 Gustafson L. Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 1987; 6 (03) 209-223
9 Neary D, Snowden JS, Northen B, Goulding P. Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry 1988; 51 (03) 353-361
10 Brun A, Englund B, Gustafson L. , et al; The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57 (04) 416-418
11 Hutton M, Lendon CL, Rizzu P. , et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393 (6686): 702-705
12 Rascovsky K, Hodges JR, Knopman D. , et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134 (Pt 9): 2456-2477
13 Gorno-Tempini ML, Hillis AE, Weintraub S. , et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76 (11) 1006-1014
14 Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009; 62 (01) 42-52
15 Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011; 24 (06) 542-549
16 Rohrer JD, Lashley T, Schott JM. , et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011; 134 (Pt 9): 2565-2581
17 Mackenzie IR, Neumann M, Baborie A. , et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122 (01) 111-113
18 Rohrer JD, Nicholas JM, Cash DM. , et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015; 14 (03) 253-262
19 Coyle-Gilchrist IT, Dick KM, Patterson K. , et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016; 86 (18) 1736-1743
20 Snowden JS, Thompson JC, Stopford CL. , et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; 134 (Pt 9): 2478-2492
21 Mesulam MM. Primary progressive aphasia and the language network: the 2013 H. Houston Merritt Lecture. Neurology 2013; 81 (05) 456-462
22 Nicholson AM, Rademakers R. What we know about TMEM106B in neurodegeneration. Acta Neuropathol 2016; 132 (05) 639-651
23 Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem 2016; 138 (Suppl. 01) 54-70
24 Rohrer JD, Guerreiro R, Vandrovcova J. , et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009; 73 (18) 1451-1456
25 Rohrer JD, Warren JD. Phenomenology and anatomy of abnormal behaviours in primary progressive aphasia. J Neurol Sci 2010; 293 (1–2): 35-38
26 Piguet O, Hodges JR. Behavioural-variant frontotemporal dementia: an update. Dement Neuropsychol 2013; 7 (01) 10-18
27 Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem 2016; 138 (Suppl. 01) 32-53
28 Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012; 8 (08) 423-434
29 Pickering-Brown SM, Rollinson S, Du Plessis D. , et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 2008; 131 (Pt 3): 721-731
30 Seelaar H, Kamphorst W, Rosso SM. , et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008; 71 (16) 1220-1226
31 Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015; 386 (10004): 1672-1682
32 Gijselinck I, Van Mossevelde S, van der Zee J. , et al; BELNEU Consortium. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 2015; 85 (24) 2116-2125
33 Mishra A, Ferrari R, Heutink P, Hardy J, Pijnenburg Y, Posthuma D. ; International FTD-Genomics Consortium. Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. Brain 2017; 140 (05) 1437-1446
34 Taskesen E, Mishra A, van der Sluis S. , et al; International FTD-Genomics Consortium. Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci Rep 2017; 7 (01) 8899
35 Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Rossor MN. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci 2013; 36 (10) 561-569
36 Mahoney CJ, Beck J, Rohrer JD. , et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012; 135 (Pt 3): 736-750
37 Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. Nat Rev Neurol 2012; 8 (03) 131-142
38 Georgiadis K, Wray S, Ourselin S, Warren JD, Modat M. Computational modelling of pathogenic protein spread in neurodegenerative diseases. PLoS One 2018; 13 (02) e0192518
39 Sami S, Williams N, Hughes LE. , et al. Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype. Brain 2018; 141 (08) 2500-2510
40 Sommerlad A, Lee J, Warren J, Price G. Neurodegenerative disorder masquerading as psychosis in a forensic psychiatry setting. BMJ Case Rep 2014; 2014: 2014
41 Ramanan S, Bertoux M, Flanagan E. , et al. Longitudinal executive function and episodic memory profiles in behavioral-variant frontotemporal dementia and Alzheimer's disease. J Int Neuropsychol Soc 2017; 23 (01) 34-43
42 Beck J, Rohrer JD, Campbell T. , et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 2008; 131 (Pt 3): 706-720
43 Devenney E, Swinn T, Mioshi E. , et al. The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study. BMC Neurol 2018; 18 (01) 56
44 Clark CN, Nicholas JM, Gordon E. , et al. Altered sense of humor in dementia. J Alzheimers Dis 2016; 49 (01) 111-119
45 Ahmed RM, Goldberg ZL, Kaizik C. , et al. Neural correlates of changes in sexual function in frontotemporal dementia: implications for reward and physiological functioning. J Neurol 2018; 265 (11) 2562-2572
46 Fletcher PD, Downey LE, Golden HL. , et al. Auditory hedonic phenotypes in dementia: a behavioural and neuroanatomical analysis. Cortex 2015; 67: 95-105
47 Fletcher PD, Downey LE, Golden HL. , et al. Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. Brain 2015; 138 (Pt 11): 3360-3372
48 Erkkinen MG, Zúñiga RG, Pardo CC, Miller BL, Miller ZA. Artistic renaissance in frontotemporal dementia. JAMA 2018; 319 (13) 1304-1306
49 Devenney EM, Landin-Romero R, Irish M. , et al. The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. Neuroimage Clin 2016; 13: 439-445
50 Hardy CJ, Buckley AH, Downey LE. , et al. The language profile of behavioral variant frontotemporal dementia. J Alzheimers Dis 2016; 50 (02) 359-371
51 Whitwell JL, Przybelski SA, Weigand SD. , et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain 2009; 132 (Pt 11): 2932-2946
52 Chan D, Anderson V, Pijnenburg Y. , et al. The clinical profile of right temporal lobe atrophy. Brain 2009; 132 (Pt 5): 1287-1298
53 Marshall CR, Hardy CJD, Russell LL. , et al. Motor signatures of emotional reactivity in frontotemporal dementia. Sci Rep 2018; 8 (01) 1030
54 Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011; 82 (11) 1274-1278
55 Marshall CR, Hardy CJD, Russell LL. , et al. Impaired interoceptive accuracy in semantic variant primary progressive aphasia. Front Neurol 2017; 8: 610
56 Irish M, Addis DR, Hodges JR, Piguet O. Considering the role of semantic memory in episodic future thinking: evidence from semantic dementia. Brain 2012; 135 (Pt 7): 2178-2191
57 Sabodash V, Mendez MF, Fong S, Hsiao JJ. Suicidal behavior in dementia: a special risk in semantic dementia. Am J Alzheimers Dis Other Demen 2013; 28 (06) 592-599
58 Kremen SA, Mendez MF, Tsai P-H, Teng E. Extrapyramidal signs in the primary progressive aphasias. Am J Alzheimers Dis Other Demen 2011; 26 (01) 72-77
59 Josephs KA, Whitwell JL, Murray ME. , et al. Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain 2013; 136 (Pt 2): 455-470
60 Warren JD, Hardy CJ, Fletcher PD. , et al. Binary reversals in primary progressive aphasia. Cortex 2016; 82: 287-289
61 Josephs KA, Duffy JR, Strand EA. , et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129 (Pt 6): 1385-1398
62 Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: a clinical and neurolinguistic analysis. Neurology 2010; 75 (07) 603-610
63 Hardy CJ, Marshall CR, Golden HL. , et al. Hearing and dementia. J Neurol 2016; 263 (11) 2339-2354
64 Rohrer JD, Rossor MN, Warren JD. Apraxia in progressive nonfluent aphasia. J Neurol 2010; 257 (04) 569-574
65 Warren JD, Warren JE, Fox NC, Warrington EK. Nothing to say, something to sing: primary progressive dynamic aphasia. Neurocase 2003; 9 (02) 140-155
66 Magdalinou NK, Golden HL, Nicholas JM. , et al. Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase 2018; 24 (04) 204-212
67 Rohrer JD, Paviour D, Bronstein AM, O'Sullivan SS, Lees A, Warren JD. Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis. Mov Disord 2010; 25 (02) 179-188
68 Rohrer JD, Crutch SJ, Warrington EK, Warren JD. Progranulin-associated primary progressive aphasia: a distinct phenotype?. Neuropsychologia 2010; 48 (01) 288-297
69 Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010; 9 (08) 793-806
70 Ahmed RM, Murphy E, Davagnanam I. , et al. A practical approach to diagnosing adult onset leukodystrophies. J Neurol Neurosurg Psychiatry 2014; 85 (07) 770-781
71 Ossenkoppele R, Pijnenburg YA, Perry DC. , et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain 2015; 138 (Pt 9): 2732-2749
72 Brodaty H, Seeher K, Gibson L. Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr 2012; 24 (07) 1034-1045
73 Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005; 128 (Pt 9): 1996-2005
74 Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15 (01) 84-87
75 Vercelletto M, Boutoleau-Bretonnière C, Volteau C. , et al; French research network on Frontotemporal dementia. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 2011; 23 (04) 749-759
76 Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58 (05) 212-216
77 Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172 (04) 400-408
78 Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17 (04) 355-359
79 Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanctôt KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 2012; 20 (09) 789-797
80 Czarnecki K, Kumar N, Josephs KA. Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?. Eur J Neurol 2008; 15 (02) 199-201
81 Nomoto H, Matsubara Y, Ichimiya Y, Arai H. A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole. Psychogeriatrics 2017; 17 (06) 509-510
82 Dick KM, van Swieten JC, Gerhard A. , et al. Symptom onset in genetic frontotemporal dementia. Alzheimers Dement 2017; 13 (Suppl. 01) 1337
83 Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem 2016; 138 (Suppl. 01) 211-221
84 Gordon E, Rohrer JD, Kim LG. , et al. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010; 74 (08) 666-673
85 Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging 2018; 6 (04) 305-316
86 Rohrer JD, Woollacott IO, Dick KM. , et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 2016; 87 (13) 1329-1336
87 Feneberg E, Steinacker P, Volk AE. , et al. Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. J Neural Transm (Vienna) 2016; 123 (03) 289-296
88 Borroni B, Benussi A, Premi E. , et al. Biological, neuroimaging, and neurophysiological markers in frontotemporal dementia: three faces of the same coin. J Alzheimers Dis 2018; 62 (03) 1113-1123
89 Foiani MS, Woollacott IO, Heller C. , et al. Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry 2018; 89 (08) 804-807
90 Woollacott IOC, Nicholas JM, Heslegrave A. , et al. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimers Res Ther 2018; 10 (01) 79
91 Ahmed RM, Ke YD, Vucic S. , et al. Physiological changes in neurodegeneration - mechanistic insights and clinical utility. Nat Rev Neurol 2018; 14 (05) 259-271
92 Kim WS, Jary E, Pickford R. , et al. Lipidomics analysis of behavioral variant frontotemporal dementia: a scope for biomarker development. Front Neurol 2018; 9: 104
93 Marshall CR, Hardy CJD, Allen M. , et al. Cardiac responses to viewing facial emotion differentiate frontotemporal dementias. Ann Clin Transl Neurol 2018; 5 (06) 687-696
94 Hu WT, McMillan C, Libon D. , et al. Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 2010; 75 (07) 595-602
95 Almeida S, Gao F, Coppola G, Gao FB. Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients. Neurobiol Aging 2016; 42: 35-40
96 Capell A, Liebscher S, Fellerer K. , et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 2011; 31 (05) 1885-1894
97 Ahmed RM, Irish M, van Eersel J. , et al. Mouse models of frontotemporal dementia: a comparison of phenotypes with clinical symptomatology. Neurosci Biobehav Rev 2017; 74 (Pt A): 126-138
98 Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol 2017; 16 (10) 837-847
99 Hardy CJD, Marshall CR, Bond RL. , et al. Retained capacity for perceptual learning of degraded speech in primary progressive aphasia and Alzheimer's disease. Alzheimers Res Ther 2018; 10 (01) 70
100 Finger E, Berry S, Cummings J. , et al. Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). Alzheimers Res Ther 2018; 10 (01) 102
101 Carthery-Goulart MT, da Silveira ADC, Machado TH. , et al. Nonpharmacological interventions for cognitive impairments following primary progressive aphasia: a systematic review of the literature. Dement Neuropsychol 2013; 7 (01) 122-131
102 Tsapkini K, Webster KT, Ficek BN. , et al. Electrical brain stimulation in different variants of primary progressive aphasia: a randomized clinical trial. Alzheimers Dement (N Y) 2018; 4: 461-472
103 Tsakiris M, Hesse MD, Boy C, Haggard P, Fink GR. Neural signatures of body ownership: a sensory network for bodily self-consciousness. Cereb Cortex 2007; 17 (10) 2235-2244
104 Downey LE, Fletcher PD, Golden HL. , et al. Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. J Neurol Neurosurg Psychiatry 2014; 85 (09) 1016-1023
105 Guo CC, Sturm VE, Zhou J. , et al. Dominant hemisphere lateralization of cortical parasympathetic control as revealed by frontotemporal dementia. Proc Natl Acad Sci U S A 2016; 113 (17) E2430-E2439